drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB09293 | DB09333 | 116 | 278 | [
"DDInter954",
"DDInter963"
] | Iodide I-131 | Iopodic acid | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Iopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6. Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was devel... | Moderate | 1 | [
[
[
116,
24,
278
]
],
[
[
116,
63,
1527
],
[
1527,
24,
278
]
],
[
[
116,
63,
1527
],
[
1527,
63,
461
],
[
461,
24,
278
]
],
[
[
116,
... | [
[
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
... | Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid and Iothalamic acid may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Iotha... |
DB00612 | DB11348 | 1,121 | 1,065 | [
"DDInter216",
"DDInter279"
] | Bisoprolol | Calcium Phosphate | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
1121,
24,
1065
]
],
[
[
1121,
1,
819
],
[
819,
24,
1065
]
],
[
[
1121,
62,
1152
],
[
1152,
24,
1065
]
],
[
[
1121,
1,
819
],
[
819,
... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Bisoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a ... | Bisoprolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Bisoprolol may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a moderate interaction t... |
DB00734 | DB09038 | 1,664 | 1,450 | [
"DDInter1605",
"DDInter636"
] | Risperidone | Empagliflozin | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1664,
24,
1450
]
],
[
[
1664,
24,
485
],
[
485,
24,
1450
]
],
[
[
1664,
24,
659
],
[
659,
63,
1450
]
],
[
[
1664,
63,
1179
],
[
1179,
... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
... | Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and... |
DB00450 | DB01211 | 78 | 609 | [
"DDInter603",
"DDInter393"
] | Droperidol | Clarithromycin | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Major | 2 | [
[
[
78,
25,
609
]
],
[
[
78,
21,
28789
],
[
28789,
60,
609
]
],
[
[
78,
64,
600
],
[
600,
23,
609
]
],
[
[
78,
24,
222
],
[
222,
23,... | [
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
]
],
[
[
"Droperidol",
"{u} (Compound) causes {v} (Side Effect)",
"Loss of consciousness"
],
[
"Loss of consciousness",
"{u} (Side Ef... | Droperidol (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Clarithromycin (Compound)
Droperidol may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken... |
DB00488 | DB01044 | 196 | 246 | [
"DDInter57",
"DDInter809"
] | Altretamine | Gatifloxacin | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Minor | 0 | [
[
[
196,
23,
246
]
],
[
[
196,
23,
739
],
[
739,
1,
246
]
],
[
[
196,
62,
1176
],
[
1176,
1,
246
]
],
[
[
196,
23,
945
],
[
945,
40,... | [
[
[
"Altretamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Altretamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
... | Altretamine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound)
Altretamine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin (... |
DB00086 | DB00215 | 1,167 | 1,230 | [
"DDInter1712",
"DDInter388"
] | Streptokinase | Citalopram | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Moderate | 1 | [
[
[
1167,
24,
1230
]
],
[
[
1167,
24,
318
],
[
318,
40,
1230
]
],
[
[
1167,
25,
500
],
[
500,
63,
1230
]
],
[
[
1167,
24,
885
],
[
885,
... | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
],
... | Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) resembles Citalopram (Compound)
Streptokinase may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exac... |
DB00524 | DB11348 | 811 | 1,065 | [
"DDInter1199",
"DDInter279"
] | Metolazone | Calcium Phosphate | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
811,
24,
1065
]
],
[
[
811,
40,
1014
],
[
1014,
24,
1065
]
],
[
[
811,
23,
1620
],
[
1620,
24,
1065
]
],
[
[
811,
1,
1605
],
[
1605,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may caus... | Metolazone (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Metolazone may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline may cause a moderate interacti... |
DB00641 | DB00995 | 467 | 1,112 | [
"DDInter1675",
"DDInter139"
] | Simvastatin | Auranofin | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme ox... | Moderate | 1 | [
[
[
467,
24,
1112
]
],
[
[
467,
7,
2067
],
[
2067,
45,
1112
]
],
[
[
467,
7,
3553
],
[
3553,
46,
1112
]
],
[
[
467,
18,
6662
],
[
6662,
... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Auranofin"
]
],
[
[
"Simvastatin",
"{u} (Compound) upregulates {v} (Gene)",
"IKBKB"
],
[
"IKBKB",
"{u} (Gene) is bound by {v} (Compou... | Simvastatin (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is bound by Auranofin (Compound)
Simvastatin (Compound) upregulates CRIP1 (Gene) and CRIP1 (Gene) is upregulated by Auranofin (Compound)
Simvastatin (Compound) downregulates POP4 (Gene) and POP4 (Gene) is downregulated by Auranofin (Compound)
Simvastatin ... |
DB00041 | DB14881 | 1,648 | 180 | [
"DDInter38",
"DDInter1329"
] | Aldesleukin | Oliceridine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1648,
24,
180
]
],
[
[
1648,
24,
401
],
[
401,
24,
180
]
],
[
[
1648,
63,
1184
],
[
1184,
24,
180
]
],
[
[
1648,
25,
375
],
[
375,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and A... |
DB00618 | DB14491 | 1,572 | 428 | [
"DDInter498",
"DDInter725"
] | Demeclocycline | Ferrous fumarate | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
1572,
24,
428
]
],
[
[
1572,
24,
1096
],
[
1096,
23,
428
]
],
[
[
1572,
24,
1384
],
[
1384,
24,
428
]
],
[
[
1572,
1,
1545
],
[
1545,
... | [
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic ... | Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00927 | DB04844 | 1,559 | 843 | [
"DDInter712",
"DDInter1778"
] | Famotidine | Tetrabenazine | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
1559,
24,
843
]
],
[
[
1559,
63,
479
],
[
479,
40,
843
]
],
[
[
1559,
21,
28698
],
[
28698,
60,
843
]
],
[
[
1559,
62,
112
],
[
112,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
... | Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Famotidine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Tetrabenazine (Compound)
Famotidine may cause a minor interaction t... |
DB00554 | DB12332 | 1,027 | 1,619 | [
"DDInter1478",
"DDInter1626"
] | Piroxicam | Rucaparib | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1027,
24,
1619
]
],
[
[
1027,
24,
222
],
[
222,
23,
1619
]
],
[
[
1027,
24,
1662
],
[
1662,
24,
1619
]
],
[
[
1027,
25,
1213
],
[
1213... | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Pi... |
DB00196 | DB00539 | 600 | 11 | [
"DDInter743",
"DDInter1837"
] | Fluconazole | Toremifene | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Major | 2 | [
[
[
600,
25,
11
]
],
[
[
600,
6,
4973
],
[
4973,
45,
11
]
],
[
[
600,
21,
28646
],
[
28646,
60,
11
]
],
[
[
600,
23,
1247
],
[
1247,
... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Toremif... | Fluconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Toremifene (Compound)
Fluconazole (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Toremifene (Compound)
Fluconazole may cause a ... |
DB00188 | DB13179 | 168 | 68 | [
"DDInter222",
"DDInter1882"
] | Bortezomib | Troleandomycin | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | A macrolide antibiotic that is similar to erythromycin. | Moderate | 1 | [
[
[
168,
24,
68
]
],
[
[
168,
23,
1101
],
[
1101,
23,
68
]
],
[
[
168,
24,
309
],
[
309,
24,
68
]
],
[
[
168,
23,
1220
],
[
1220,
24... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
... | Bortezomib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabe... |
DB00065 | DB00622 | 581 | 1,081 | [
"DDInter923",
"DDInter1287"
] | Infliximab | Nicardipine | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Moderate | 1 | [
[
[
581,
24,
1081
]
],
[
[
581,
24,
409
],
[
409,
1,
1081
]
],
[
[
581,
25,
1583
],
[
1583,
63,
1081
]
],
[
[
581,
24,
1593
],
[
1593,
... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nicardipine"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine (Compound) resembles Nicardipine (Compound)
Infliximab may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate dise... |
DB00242 | DB09052 | 1,064 | 250 | [
"DDInter392",
"DDInter220"
] | Cladribine | Blinatumomab | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Major | 2 | [
[
[
1064,
25,
250
]
],
[
[
1064,
24,
949
],
[
949,
63,
250
]
],
[
[
1064,
25,
1362
],
[
1362,
63,
250
]
],
[
[
1064,
64,
305
],
[
305,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (forma... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Cladribine... |
DB04911 | DB08881 | 968 | 868 | [
"DDInter1347",
"DDInter1925"
] | Oritavancin | Vemurafenib | Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
968,
24,
868
]
],
[
[
968,
21,
29015
],
[
29015,
60,
868
]
],
[
[
968,
62,
168
],
[
168,
23,
868
]
],
[
[
968,
24,
578
],
[
578,
... | [
[
[
"Oritavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Oritavancin",
"{u} (Compound) causes {v} (Side Effect)",
"Eosinophilia"
],
[
"Eosinophilia",
"{u} (Side Effect... | Oritavancin (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafenib (Compound)
Oritavancin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Ve... |
DB01404 | DB06209 | 757 | 256 | [
"DDInter820",
"DDInter1508"
] | Ginseng | Prasugrel | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Moderate | 1 | [
[
[
757,
24,
256
]
],
[
[
757,
63,
1479
],
[
1479,
24,
256
]
],
[
[
757,
24,
578
],
[
578,
63,
256
]
],
[
[
757,
63,
1317
],
[
1317,
... | [
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[... | Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Ticagrel... |
DB09061 | DB11901 | 1,627 | 913 | [
"DDInter284",
"DDInter107"
] | Cannabidiol | Apalutamide | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1627,
24,
913
]
],
[
[
1627,
62,
600
],
[
600,
24,
913
]
],
[
[
1627,
24,
1320
],
[
1320,
63,
913
]
],
[
[
1627,
63,
1250
],
[
1250,
... | [
[
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Cannabidiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
],
[
... | Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elago... |
DB00095 | DB00928 | 66 | 1,426 | [
"DDInter623",
"DDInter148"
] | Efalizumab | Azacitidine | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. ... | Moderate | 1 | [
[
[
66,
24,
1426
]
],
[
[
66,
24,
1238
],
[
1238,
40,
1426
]
],
[
[
66,
24,
372
],
[
372,
1,
1426
]
],
[
[
66,
25,
1064
],
[
1064,
2... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azacitidine"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
],
[
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin (Compound) resembles Azacitidine (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) resembles Azacitidine (Comp... |
DB00848 | DB11627 | 281 | 1,367 | [
"DDInter1044",
"DDInter860"
] | Levamisole | Hepatitis B Vaccine (Recombinant) | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this,... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
281,
24,
1367
]
],
[
[
281,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
281,
24,
259
],
[
259,
24,
1367
]
],
[
[
281,
25,
375
],
[
375,
... | [
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Levamisole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
... | Levamisole may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept an... |
DB00445 | DB01246 | 322 | 820 | [
"DDInter655",
"DDInter45"
] | Epirubicin | Alimemazine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
322,
24,
820
]
],
[
[
322,
24,
401
],
[
401,
24,
820
]
],
[
[
322,
24,
675
],
[
675,
25,
820
]
],
[
[
322,
63,
508
],
[
508,
1,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphe... |
DB10429 | DB11569 | 200 | 1,093 | [
"DDInter282",
"DDInter1003"
] | Candida albicans | Ixekizumab | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Moderate | 1 | [
[
[
200,
24,
1093
]
],
[
[
200,
63,
134
],
[
134,
24,
1093
]
],
[
[
200,
24,
270
],
[
270,
63,
1093
]
],
[
[
200,
63,
1057
],
[
1057,
... | [
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
... | Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Ocreliz... |
DB08816 | DB08918 | 578 | 41 | [
"DDInter1802",
"DDInter1059"
] | Ticagrelor | Levomilnacipran | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Moderate | 1 | [
[
[
578,
24,
41
]
],
[
[
578,
63,
901
],
[
901,
40,
41
]
],
[
[
578,
6,
4973
],
[
4973,
45,
41
]
],
[
[
578,
21,
28847
],
[
28847,
6... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
... | Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Ticagrelor (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Levomilnacipran (Compound)
Ticagrelor (Compound) causes Eye disorder (Side Effect) ... |
DB00563 | DB00808 | 663 | 1,605 | [
"DDInter1174",
"DDInter916"
] | Methotrexate | Indapamide | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Moderate | 1 | [
[
[
663,
24,
1605
]
],
[
[
663,
63,
811
],
[
811,
1,
1605
]
],
[
[
663,
21,
28640
],
[
28640,
60,
1605
]
],
[
[
663,
24,
1669
],
[
1669,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Indapamide (Compound)
Methotrexate (Compound) causes Depression (Side Effect) and Depression (Side Effect) is caused by Indapamide (Compound)
Methotrexate may cause a moderate inte... |
DB00526 | DB00679 | 1,555 | 684 | [
"DDInter1355",
"DDInter1796"
] | Oxaliplatin | Thioridazine | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Major | 2 | [
[
[
1555,
25,
684
]
],
[
[
1555,
24,
1237
],
[
1237,
40,
684
]
],
[
[
1555,
63,
216
],
[
216,
1,
684
]
],
[
[
1555,
24,
9
],
[
9,
1,... | [
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
[
"Clom... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Thioridazine (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) resembles Thiori... |
DB00912 | DB11255 | 473 | 1,371 | [
"DDInter1581",
"DDInter374"
] | Repaglinide | Chromium picolinate | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. Chromium ions are show... | Moderate | 1 | [
[
[
473,
24,
1371
]
],
[
[
473,
24,
5
],
[
5,
24,
1371
]
],
[
[
473,
63,
1645
],
[
1645,
24,
1371
]
],
[
[
473,
24,
1385
],
[
1385,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Metformi... |
DB00486 | DB08822 | 1,614 | 911 | [
"DDInter1253",
"DDInter156"
] | Nabilone | Azilsartan medoxomil | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in ... | Moderate | 1 | [
[
[
1614,
24,
911
]
],
[
[
1614,
63,
217
],
[
217,
1,
911
]
],
[
[
1614,
24,
240
],
[
240,
1,
911
]
],
[
[
1614,
21,
29093
],
[
29093,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmesartan"
],
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Losartan and Losartan (Compound) resembles Azilsartan medoxomil... |
DB00011 | DB01611 | 1,451 | 1,487 | [
"DDInter944",
"DDInter893"
] | Interferon alfa-n1 | Hydroxychloroquine | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
1451,
24,
1487
]
],
[
[
1451,
24,
663
],
[
663,
23,
1487
]
],
[
[
1451,
24,
168
],
[
168,
24,
1487
]
],
[
[
1451,
25,
139
],
[
139,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Met... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Hydroxychloroquine
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00361 | DB00649 | 134 | 231 | [
"DDInter1939",
"DDInter1710"
] | Vinorelbine | Stavudine | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | Moderate | 1 | [
[
[
134,
24,
231
]
],
[
[
134,
24,
1477
],
[
1477,
40,
231
]
],
[
[
134,
24,
139
],
[
139,
1,
231
]
],
[
[
134,
63,
141
],
[
141,
1,... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stavudine"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
],
[
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine and Telbivudine (Compound) resembles Stavudine (Compound)
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) resembles Stavudine (Compound... |
DB01168 | DB05679 | 1,053 | 1,683 | [
"DDInter1526",
"DDInter1907"
] | Procarbazine | Ustekinumab | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
1053,
24,
1683
]
],
[
[
1053,
63,
1461
],
[
1461,
23,
1683
]
],
[
[
1053,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
1053,
63,
409
],
[
409... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
... | Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olapari... |
DB00477 | DB01177 | 216 | 77 | [
"DDInter363",
"DDInter904"
] | Chlorpromazine | Idarubicin | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
216,
24,
77
]
],
[
[
216,
6,
12523
],
[
12523,
45,
77
]
],
[
[
216,
7,
2703
],
[
2703,
46,
77
]
],
[
[
216,
18,
5218
],
[
5218,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Com... | Chlorpromazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Idarubicin (Compound)
Chlorpromazine (Compound) upregulates IKZF1 (Gene) and IKZF1 (Gene) is upregulated by Idarubicin (Compound)
Chlorpromazine (Compound) downregulates UBE2C (Gene) and UBE2C (Gene) is downregulated by Idarubicin (Compound)
Ch... |
DB00445 | DB11817 | 322 | 1,259 | [
"DDInter655",
"DDInter165"
] | Epirubicin | Baricitinib | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
322,
25,
1259
]
],
[
[
322,
63,
1461
],
[
1461,
23,
1259
]
],
[
[
322,
24,
949
],
[
949,
24,
1259
]
],
[
[
322,
24,
1129
],
[
1129,
... | [
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E"... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoi... |
DB01098 | DB12332 | 14 | 1,619 | [
"DDInter1622",
"DDInter1626"
] | Rosuvastatin | Rucaparib | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
14,
24,
1619
]
],
[
[
14,
63,
112
],
[
112,
23,
1619
]
],
[
[
14,
24,
309
],
[
309,
24,
1619
]
],
[
[
14,
25,
1501
],
[
1501,
63... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone an... |
DB00067 | DB01259 | 317 | 392 | [
"DDInter1921",
"DDInter1024"
] | Vasopressin | Lapatinib | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
317,
24,
392
]
],
[
[
317,
23,
112
],
[
112,
23,
392
]
],
[
[
317,
24,
918
],
[
918,
24,
392
]
],
[
[
317,
24,
1151
],
[
1151,
6... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and B... |
DB00816 | DB11853 | 1,674 | 230 | [
"DDInter1346",
"DDInter1577"
] | Orciprenaline | Relugolix | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Moderate | 1 | [
[
[
1674,
24,
230
]
],
[
[
1674,
24,
129
],
[
129,
23,
230
]
],
[
[
1674,
24,
480
],
[
480,
24,
230
]
],
[
[
1674,
63,
79
],
[
79,
2... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and... |
DB00852 | DB01253 | 1,445 | 628 | [
"DDInter1545",
"DDInter664"
] | Pseudoephedrine | Ergometrine | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Major | 2 | [
[
[
1445,
25,
628
]
],
[
[
1445,
64,
1131
],
[
1131,
40,
628
]
],
[
[
1445,
24,
469
],
[
469,
40,
628
]
],
[
[
1445,
6,
5214
],
[
5214,
... | [
[
[
"Pseudoephedrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ergometrine"
]
],
[
[
"Pseudoephedrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methysergide"
],
[
"Methysergide... | Pseudoephedrine may lead to a major life threatening interaction when taken with Methysergide and Methysergide (Compound) resembles Ergometrine (Compound)
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine and Bromocriptine (Compound) resembles Ergometrine (Com... |
DB00163 | DB06209 | 1,461 | 256 | [
"DDInter1943",
"DDInter1508"
] | Vitamin E | Prasugrel | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Moderate | 1 | [
[
[
1461,
24,
256
]
],
[
[
1461,
24,
450
],
[
450,
23,
256
]
],
[
[
1461,
24,
1479
],
[
1479,
24,
256
]
],
[
[
1461,
24,
578
],
[
578,
... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
[... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicyli... |
DB01142 | DB05294 | 1,264 | 1,069 | [
"DDInter593",
"DDInter1917"
] | Doxepin | Vandetanib | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
1264,
25,
1069
]
],
[
[
1264,
6,
6943
],
[
6943,
45,
1069
]
],
[
[
1264,
21,
28719
],
[
28719,
60,
1069
]
],
[
[
1264,
62,
1247
],
[
1... | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Doxepin",
"{u} (Compound) binds {v} (Gene)",
"ORM1"
],
[
"ORM1",
"{u} (Gene) is bound by {v} (Compound)",
"Vandetanib"
]... | Doxepin (Compound) binds ORM1 (Gene) and ORM1 (Gene) is bound by Vandetanib (Compound)
Doxepin (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Vandetanib (Compound)
Doxepin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may ca... |
DB06273 | DB09122 | 980 | 1,613 | [
"DDInter1824",
"DDInter1409"
] | Tocilizumab | Peginterferon beta-1a | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
980,
24,
1613
]
],
[
[
980,
63,
671
],
[
671,
24,
1613
]
],
[
[
980,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
980,
24,
975
],
[
975,
... | [
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
... | Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Cannab... |
DB00758 | DB03619 | 1,347 | 557 | [
"DDInter413",
"DDInter501"
] | Clopidogrel | Deoxycholic acid | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic... | Moderate | 1 | [
[
[
1347,
24,
557
]
],
[
[
1347,
24,
1479
],
[
1479,
24,
557
]
],
[
[
1347,
64,
126
],
[
126,
24,
557
]
],
[
[
1347,
25,
405
],
[
405,
... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic aci... | Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid
Clopidogrel may lead to a major life threatening interaction when taken with Warfarin... |
DB00191 | DB00472 | 73 | 758 | [
"DDInter1447",
"DDInter758"
] | Phentermine | Fluoxetine | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Major | 2 | [
[
[
73,
25,
758
]
],
[
[
73,
25,
109
],
[
109,
40,
758
]
],
[
[
73,
6,
12523
],
[
12523,
45,
758
]
],
[
[
73,
21,
30068
],
[
30068,
... | [
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluoxetine"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u}... | Phentermine may lead to a major life threatening interaction when taken with Duloxetine and Duloxetine (Compound) resembles Fluoxetine (Compound)
Phentermine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fluoxetine (Compound)
Phentermine (Compound) causes Pulmonary hypertension (Side Effect) and Pulmonar... |
DB00019 | DB00762 | 1,257 | 613 | [
"DDInter1405",
"DDInter973"
] | Pegfilgrastim | Irinotecan | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Moderate | 1 | [
[
[
1257,
24,
613
]
],
[
[
1257,
24,
869
],
[
869,
63,
613
]
],
[
[
1257,
24,
599
],
[
599,
24,
613
]
],
[
[
1257,
24,
770
],
[
770,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and A... |
DB00468 | DB00697 | 1,424 | 876 | [
"DDInter1557",
"DDInter1821"
] | Quinine | Tizanidine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debi... | Moderate | 1 | [
[
[
1424,
24,
876
]
],
[
[
1424,
6,
7950
],
[
7950,
45,
876
]
],
[
[
1424,
21,
28882
],
[
28882,
60,
876
]
],
[
[
1424,
23,
112
],
[
112,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Quinine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Tizanidine (Compound)
Quinine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Tizanidine (Compound)
Quinine may cause a minor interaction that can limit clinical effects when taken w... |
DB00574 | DB08881 | 121 | 868 | [
"DDInter717",
"DDInter1925"
] | Fenfluramine | Vemurafenib | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
121,
24,
868
]
],
[
[
121,
23,
211
],
[
211,
23,
868
]
],
[
[
121,
24,
271
],
[
271,
62,
868
]
],
[
[
121,
25,
1405
],
[
1405,
2... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Fenfluramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolterodine"
],
... | Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron and Mir... |
DB00857 | DB01125 | 1,387 | 279 | [
"DDInter1768",
"DDInter98"
] | Terbinafine | Anisindione | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Moderate | 1 | [
[
[
1387,
24,
279
]
],
[
[
1387,
24,
913
],
[
913,
63,
279
]
],
[
[
1387,
63,
912
],
[
912,
24,
279
]
],
[
[
1387,
62,
752
],
[
752,
... | [
[
[
"Terbinafine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Terbinafine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
... | Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-... |
DB00308 | DB00916 | 347 | 112 | [
"DDInter901",
"DDInter1202"
] | Ibutilide | Metronidazole | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Minor | 0 | [
[
[
347,
23,
112
]
],
[
[
347,
21,
28789
],
[
28789,
60,
112
]
],
[
[
347,
64,
618
],
[
618,
23,
112
]
],
[
[
347,
25,
51
],
[
51,
2... | [
[
[
"Ibutilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Ibutilide",
"{u} (Compound) causes {v} (Side Effect)",
"Loss of consciousness"
],
[
"Loss of consciousness",
"{u... | Ibutilide (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Metronidazole (Compound)
Ibutilide may lead to a major life threatening interaction when taken with Abarelix and Abarelix may cause a minor interaction that can limit clinical effects when taken with Met... |
DB00334 | DB01177 | 867 | 77 | [
"DDInter1326",
"DDInter904"
] | Olanzapine | Idarubicin | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
867,
24,
77
]
],
[
[
867,
6,
6017
],
[
6017,
45,
77
]
],
[
[
867,
7,
5178
],
[
5178,
57,
77
]
],
[
[
867,
23,
112
],
[
112,
23,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Olanzapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",... | Olanzapine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Idarubicin (Compound)
Olanzapine (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is downregulated by Idarubicin (Compound)
Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole m... |
DB00970 | DB05679 | 0 | 1,683 | [
"DDInter466",
"DDInter1907"
] | Dactinomycin | Ustekinumab | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
0,
24,
1683
]
],
[
[
0,
63,
1461
],
[
1461,
23,
1683
]
],
[
[
0,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
0,
24,
1307
],
[
1307,
24... | [
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
... | Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olapari... |
DB00927 | DB11837 | 1,559 | 1,297 | [
"DDInter712",
"DDInter1351"
] | Famotidine | Osilodrostat | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
1559,
24,
1297
]
],
[
[
1559,
62,
112
],
[
112,
23,
1297
]
],
[
[
1559,
23,
1247
],
[
1247,
23,
1297
]
],
[
[
1559,
24,
623
],
[
623,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Famotidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Famotidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole an... |
DB00030 | DB00647 | 1,685 | 675 | [
"DDInter934",
"DDInter528"
] | Insulin human | Dextropropoxyphene | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Moderate | 1 | [
[
[
1685,
24,
675
]
],
[
[
1685,
24,
494
],
[
494,
1,
675
]
],
[
[
1685,
24,
954
],
[
954,
40,
675
]
],
[
[
1685,
24,
688
],
[
688,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Dextropropoxyphene (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Dextro... |
DB00694 | DB14811 | 51 | 385 | [
"DDInter485",
"DDInter979"
] | Daunorubicin | Isatuximab | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic an... | Moderate | 1 | [
[
[
51,
24,
385
]
],
[
[
51,
24,
1362
],
[
1362,
24,
385
]
],
[
[
51,
63,
377
],
[
377,
24,
385
]
],
[
[
51,
25,
770
],
[
770,
24,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomyc... |
DB00067 | DB01087 | 317 | 1,520 | [
"DDInter1921",
"DDInter1520"
] | Vasopressin | Primaquine | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Moderate | 1 | [
[
[
317,
24,
1520
]
],
[
[
317,
25,
1487
],
[
1487,
64,
1520
]
],
[
[
317,
23,
112
],
[
112,
23,
1520
]
],
[
[
317,
24,
618
],
[
618,
... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Vasopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"... | Vasopressin may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may... |
DB00601 | DB15091 | 453 | 676 | [
"DDInter1073",
"DDInter1901"
] | Linezolid | Upadacitinib | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
453,
25,
676
]
],
[
[
453,
24,
1430
],
[
1430,
24,
676
]
],
[
[
453,
63,
597
],
[
597,
24,
676
]
],
[
[
453,
63,
1184
],
[
1184,
... | [
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleuc... | Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol a... |
DB00679 | DB08875 | 684 | 1,618 | [
"DDInter1796",
"DDInter262"
] | Thioridazine | Cabozantinib | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
684,
25,
1618
]
],
[
[
684,
23,
112
],
[
112,
23,
1618
]
],
[
[
684,
25,
1662
],
[
1662,
63,
1618
]
],
[
[
684,
24,
480
],
[
480,
... | [
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Thioridazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Met... | Thioridazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Thioridazine may lead to a major life threatening interaction when taken with Picosulfuric acid and Picosu... |
DB06273 | DB06674 | 980 | 908 | [
"DDInter1824",
"DDInter837"
] | Tocilizumab | Golimumab | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
980,
25,
908
]
],
[
[
980,
23,
1193
],
[
1193,
62,
908
]
],
[
[
980,
62,
1461
],
[
1461,
23,
908
]
],
[
[
980,
63,
336
],
[
336,
... | [
[
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Tocilizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gl... | Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Golimumab
Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vita... |
DB00258 | DB00489 | 666 | 17 | [
"DDInter270",
"DDInter1704"
] | Calcium acetate | Sotalol | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Moderate | 1 | [
[
[
666,
24,
17
]
],
[
[
666,
24,
88
],
[
88,
40,
17
]
],
[
[
666,
21,
28719
],
[
28719,
60,
17
]
],
[
[
666,
24,
542
],
[
542,
23,
... | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
... | Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Sotalol (Compound)
Calcium acetate (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Sotalol (Compound)
Calcium acetate may cause a moderate interaction t... |
DB00041 | DB01232 | 1,648 | 1,327 | [
"DDInter38",
"DDInter1640"
] | Aldesleukin | Saquinavir | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Moderate | 1 | [
[
[
1648,
24,
1327
]
],
[
[
1648,
24,
798
],
[
798,
40,
1327
]
],
[
[
1648,
25,
770
],
[
770,
24,
1327
]
],
[
[
1648,
24,
891
],
[
891,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Aldesleukin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate... |
DB00424 | DB01173 | 19 | 358 | [
"DDInter896",
"DDInter1349"
] | Hyoscyamine | Orphenadrine | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Moderate | 1 | [
[
[
19,
24,
358
]
],
[
[
19,
24,
211
],
[
211,
1,
358
]
],
[
[
19,
24,
272
],
[
272,
24,
358
]
],
[
[
19,
24,
820
],
[
820,
63,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Orphenadrine (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate inte... |
DB00446 | DB00544 | 597 | 970 | [
"DDInter351",
"DDInter757"
] | Chloramphenicol | Fluorouracil | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Moderate | 1 | [
[
[
597,
24,
970
]
],
[
[
597,
24,
132
],
[
132,
1,
970
]
],
[
[
597,
6,
3486
],
[
3486,
45,
970
]
],
[
[
597,
21,
28719
],
[
28719,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Uracil mustard"... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Uracil mustard and Uracil mustard (Compound) resembles Fluorouracil (Compound)
Chloramphenicol (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Fluorouracil (Compound)
Chloramphenicol (Compound) causes Pain (Side... |
DB01255 | DB14568 | 633 | 982 | [
"DDInter1078",
"DDInter1000"
] | Lisdexamfetamine | Ivosidenib | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
633,
25,
982
]
],
[
[
633,
62,
112
],
[
112,
23,
982
]
],
[
[
633,
63,
543
],
[
543,
24,
982
]
],
[
[
633,
24,
28
],
[
28,
24,
... | [
[
[
"Lisdexamfetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Lisdexamfetamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Lisdexamfetamine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Loperam... |
DB11730 | DB11901 | 351 | 913 | [
"DDInter1588",
"DDInter107"
] | Ribociclib | Apalutamide | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
351,
25,
913
]
],
[
[
351,
64,
312
],
[
312,
23,
913
]
],
[
[
351,
62,
112
],
[
112,
23,
913
]
],
[
[
351,
24,
110
],
[
110,
62,... | [
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} ... | Ribociclib may lead to a major life threatening interaction when taken with Eplerenone and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Ribociclib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cau... |
DB00776 | DB00860 | 1,335 | 891 | [
"DDInter1360",
"DDInter1513"
] | Oxcarbazepine | Prednisolone | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
1335,
24,
891
]
],
[
[
1335,
63,
175
],
[
175,
40,
891
]
],
[
[
1335,
24,
1547
],
[
1547,
1,
891
]
],
[
[
1335,
63,
167
],
[
167,
... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
... | Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Exemestane and Exemestane (Compound) resembles Predniso... |
DB00180 | DB00867 | 1,351 | 1,052 | [
"DDInter749",
"DDInter1606"
] | Flunisolide | Ritodrine | Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors. | Adrenergic beta-agonist used to control premature labor. | Minor | 0 | [
[
[
1351,
23,
1052
]
],
[
[
1351,
1,
175
],
[
175,
23,
1052
]
],
[
[
1351,
40,
423
],
[
423,
62,
1052
]
],
[
[
1351,
40,
1573
],
[
1573,
... | [
[
[
"Flunisolide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ritodrine"
]
],
[
[
"Flunisolide",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a mi... | Flunisolide (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Ritodrine
Flunisolide (Compound) resembles Ciclesonide (Compound) and Ciclesonide may cause a minor interaction that can limit clinical effects when taken with Ritodr... |
DB05812 | DB06616 | 1,374 | 594 | [
"DDInter8",
"DDInter224"
] | Abiraterone | Bosutinib | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
1374,
24,
594
]
],
[
[
1374,
6,
8374
],
[
8374,
45,
594
]
],
[
[
1374,
21,
29231
],
[
29231,
60,
594
]
],
[
[
1374,
62,
112
],
[
112,
... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Abiraterone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Abiraterone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Abiraterone (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Bosutinib (Compound)
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Metron... |
DB00637 | DB08820 | 1,557 | 1,478 | [
"DDInter128",
"DDInter997"
] | Astemizole | Ivacaftor | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
1557,
24,
1478
]
],
[
[
1557,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
1557,
23,
307
],
[
307,
23,
1478
]
],
[
[
1557,
25,
318
],
[
318,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Astemizole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Astemizole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Astemizole may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Astemizole may lead to a m... |
DB00005 | DB00432 | 1,057 | 1,083 | [
"DDInter687",
"DDInter1868"
] | Etanercept | Trifluridine | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine] . It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activit... | Major | 2 | [
[
[
1057,
25,
1083
]
],
[
[
1057,
24,
1477
],
[
1477,
40,
1083
]
],
[
[
1057,
25,
1238
],
[
1238,
1,
1083
]
],
[
[
1057,
25,
139
],
[
139,... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
],
[
"Telbivu... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine and Telbivudine (Compound) resembles Trifluridine (Compound)
Etanercept may lead to a major life threatening interaction when taken with Pentostatin and Pentostatin (Compound) resembles Trifluridine (Compound)
Etanerc... |
DB00358 | DB12887 | 1,010 | 1,598 | [
"DDInter1140",
"DDInter1750"
] | Mefloquine | Tazemetostat | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
1010,
24,
1598
]
],
[
[
1010,
63,
608
],
[
608,
23,
1598
]
],
[
[
1010,
24,
594
],
[
594,
24,
1598
]
],
[
[
1010,
25,
985
],
[
985,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib... |
DB00022 | DB09498 | 268 | 810 | [
"DDInter1408",
"DDInter1715"
] | Peginterferon alfa-2b | Strontium chloride Sr-89 | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
268,
24,
810
]
],
[
[
268,
24,
1555
],
[
1555,
24,
810
]
],
[
[
268,
25,
139
],
[
139,
24,
810
]
],
[
[
268,
24,
1060
],
[
1060,
... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}"... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Peginterferon alfa-2b may lead to a major life threatening interaction when taken wit... |
DB00637 | DB11642 | 1,557 | 938 | [
"DDInter128",
"DDInter1480"
] | Astemizole | Pitolisant | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
1557,
24,
938
]
],
[
[
1557,
23,
112
],
[
112,
23,
938
]
],
[
[
1557,
24,
28
],
[
28,
24,
938
]
],
[
[
1557,
64,
600
],
[
600,
2... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Astemizole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisac... |
DB04953 | DB09330 | 495 | 985 | [
"DDInter708",
"DDInter1352"
] | Ezogabine | Osimertinib | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
495,
25,
985
]
],
[
[
495,
62,
112
],
[
112,
23,
985
]
],
[
[
495,
63,
480
],
[
480,
24,
985
]
],
[
[
495,
24,
119
],
[
119,
63,... | [
[
[
"Ezogabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Ezogabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Ezogabine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formo... |
DB00176 | DB12500 | 529 | 283 | [
"DDInter770",
"DDInter714"
] | Fluvoxamine | Fedratinib | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
529,
24,
283
]
],
[
[
529,
23,
466
],
[
466,
62,
283
]
],
[
[
529,
24,
351
],
[
351,
23,
283
]
],
[
[
529,
24,
1419
],
[
1419,
2... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fluvoxamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
... | Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribo... |
DB00834 | DB01246 | 932 | 820 | [
"DDInter1215",
"DDInter45"
] | Mifepristone | Alimemazine | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | A phenothiazine derivative that is used as an antipruritic. | Major | 2 | [
[
[
932,
25,
820
]
],
[
[
932,
25,
401
],
[
401,
24,
820
]
],
[
[
932,
6,
8374
],
[
8374,
45,
820
]
],
[
[
932,
7,
7669
],
[
7669,
4... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
]
],
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
... | Mifepristone may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Mifepristone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alimemazine (Compound)
Mifepristone (Compound)... |
DB00652 | DB11817 | 234 | 1,259 | [
"DDInter1421",
"DDInter165"
] | Pentazocine | Baricitinib | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Moderate | 1 | [
[
[
234,
24,
1259
]
],
[
[
234,
25,
407
],
[
407,
24,
1259
]
],
[
[
234,
64,
475
],
[
475,
24,
1259
]
],
[
[
234,
1,
1359
],
[
1359,
... | [
[
[
"Pentazocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Pentazocine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
],
[
"Opium",
... | Pentazocine may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Pentazocine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction tha... |
DB01039 | DB09054 | 535 | 384 | [
"DDInter718",
"DDInter905"
] | Fenofibrate | Idelalisib | Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
535,
24,
384
]
],
[
[
535,
63,
305
],
[
305,
24,
384
]
],
[
[
535,
24,
780
],
[
780,
24,
384
]
],
[
[
535,
40,
831
],
[
831,
24,... | [
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia ... | Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Fenofibrate may cause a moderate interaction that could exacerbate diseas... |
DB00831 | DB08868 | 1,178 | 1,011 | [
"DDInter1866",
"DDInter737"
] | Trifluoperazine | Fingolimod | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1178,
25,
1011
]
],
[
[
1178,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
1178,
23,
112
],
[
112,
23,
1011
]
],
[
[
1178,
24,
144
],
[
144... | [
[
[
"Trifluoperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac arrest"
],
[
"Cardiac arrest",
"{u} (Side Effect) is... | Trifluoperazine (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects w... |
DB00598 | DB09082 | 1,523 | 659 | [
"DDInter1013",
"DDInter1934"
] | Labetalol | Vilanterol | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Major | 2 | [
[
[
1523,
25,
659
]
],
[
[
1523,
24,
1220
],
[
1220,
23,
659
]
],
[
[
1523,
63,
251
],
[
251,
23,
659
]
],
[
[
1523,
24,
1296
],
[
1296,
... | [
[
[
"Labetalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vilanterol"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexametha... | Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and B... |
DB01229 | DB11817 | 973 | 1,259 | [
"DDInter1377",
"DDInter165"
] | Paclitaxel | Baricitinib | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
973,
25,
1259
]
],
[
[
973,
63,
1461
],
[
1461,
23,
1259
]
],
[
[
973,
24,
949
],
[
949,
24,
1259
]
],
[
[
973,
63,
563
],
[
563,
... | [
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E"... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoi... |
DB00679 | DB06292 | 684 | 549 | [
"DDInter1796",
"DDInter474"
] | Thioridazine | Dapagliflozin | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
684,
24,
549
]
],
[
[
684,
24,
1344
],
[
1344,
40,
549
]
],
[
[
684,
6,
12523
],
[
12523,
45,
549
]
],
[
[
684,
21,
28882
],
[
28882,
... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Thioridazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dapagliflozin (Compound)
Thioridazine (Compound) causes Body temperature in... |
DB00305 | DB00570 | 377 | 147 | [
"DDInter1232",
"DDInter1936"
] | Mitomycin | Vinblastine | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Moderate | 1 | [
[
[
377,
24,
147
]
],
[
[
377,
24,
134
],
[
134,
24,
147
]
],
[
[
377,
6,
4973
],
[
4973,
45,
147
]
],
[
[
377,
7,
2423
],
[
2423,
4... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
... | Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Mitomycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Vinblastine (Compound)
Mitomycin (Compoun... |
DB00500 | DB00912 | 24 | 473 | [
"DDInter1831",
"DDInter1581"
] | Tolmetin | Repaglinide | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
24,
24,
473
]
],
[
[
24,
21,
28763
],
[
28763,
60,
473
]
],
[
[
24,
24,
1512
],
[
1512,
24,
473
]
],
[
[
24,
63,
1645
],
[
1645,
... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Tolmetin",
"{u} (Compound) causes {v} (Side Effect)",
"Chest pain"
],
[
"Chest pain",
"{u} (Side Effect) is cause... | Tolmetin (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Repaglinide (Compound)
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Repaglin... |
DB00626 | DB09268 | 1,441 | 1,662 | [
"DDInter161",
"DDInter1464"
] | Bacitracin | Picosulfuric acid | Bacitracin is a combination of at least 9 bacitracins.[A955,A181952] 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy. Bacitracin was granted FDA approval on 29 July 1948.[A... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1441,
24,
1662
]
],
[
[
1441,
63,
91
],
[
91,
24,
1662
]
],
[
[
1441,
25,
361
],
[
361,
24,
1662
]
],
[
[
1441,
25,
1381
],
[
1381,
... | [
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vancomycin"
],
... | Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Bacitracin may lead to a major life threatening interaction when taken with Neomycin and Neomycin may cau... |
DB06603 | DB06674 | 39 | 908 | [
"DDInter1387",
"DDInter837"
] | Panobinostat | Golimumab | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
39,
25,
908
]
],
[
[
39,
63,
336
],
[
336,
24,
908
]
],
[
[
39,
64,
697
],
[
697,
24,
908
]
],
[
[
39,
24,
200
],
[
200,
63,
... | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedip... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Panobinostat may lead to a major life threatening interaction when taken with Phenobarbital and Phenobarbital m... |
DB00295 | DB00599 | 475 | 682 | [
"DDInter1244",
"DDInter1795"
] | Morphine | Thiopental | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does no... | Moderate | 1 | [
[
[
475,
24,
682
]
],
[
[
475,
25,
1023
],
[
1023,
1,
682
]
],
[
[
475,
6,
8374
],
[
8374,
45,
682
]
],
[
[
475,
24,
752
],
[
752,
2... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiopental"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentobarbital"
],
[
"Pentobarbit... | Morphine may lead to a major life threatening interaction when taken with Pentobarbital and Pentobarbital (Compound) resembles Thiopental (Compound)
Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Thiopental (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when t... |
DB01136 | DB06703 | 772 | 619 | [
"DDInter305",
"DDInter793"
] | Carvedilol | Gadobutrol | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age. Due to its physicochemical properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to ot... | Moderate | 1 | [
[
[
772,
24,
619
]
],
[
[
772,
21,
28643
],
[
28643,
60,
619
]
],
[
[
772,
24,
1013
],
[
1013,
63,
619
]
],
[
[
772,
21,
28643
],
[
28643,... | [
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobutrol"
]
],
[
[
"Carvedilol",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect) is caus... | Carvedilol (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Gadobutrol (Compound)
Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid and Tyropanoic acid may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00099 | DB00515 | 440 | 589 | [
"DDInter735",
"DDInter387"
] | Filgrastim | Cisplatin | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Moderate | 1 | [
[
[
440,
24,
589
]
],
[
[
440,
24,
1399
],
[
1399,
62,
589
]
],
[
[
440,
24,
1468
],
[
1468,
63,
589
]
],
[
[
440,
63,
367
],
[
367,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a minor interaction that can limit clinical effects when taken with Cisplatin
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib ... |
DB00241 | DB00468 | 288 | 1,424 | [
"DDInter257",
"DDInter1557"
] | Butalbital | Quinine | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Moderate | 1 | [
[
[
288,
24,
1424
]
],
[
[
288,
24,
1135
],
[
1135,
62,
1424
]
],
[
[
288,
24,
964
],
[
964,
23,
1424
]
],
[
[
288,
23,
752
],
[
752,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Quinine
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline ... |
DB00358 | DB01059 | 1,010 | 956 | [
"DDInter1140",
"DDInter1313"
] | Mefloquine | Norfloxacin | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Moderate | 1 | [
[
[
1010,
24,
956
]
],
[
[
1010,
24,
872
],
[
872,
40,
956
]
],
[
[
1010,
64,
1176
],
[
1176,
1,
956
]
],
[
[
1010,
24,
1539
],
[
1539,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
],
[... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Mefloquine may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Compound)
Meflo... |
DB08879 | DB10316 | 632 | 334 | [
"DDInter173",
"DDInter1248"
] | Belimumab | Mumps virus strain B level jeryl lynn live antigen | Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE).[A2... | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
632,
25,
334
]
],
[
[
632,
64,
1057
],
[
1057,
25,
334
]
],
[
[
632,
25,
976
],
[
976,
25,
334
]
],
[
[
632,
63,
599
],
[
599,
2... | [
[
[
"Belimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Belimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
... | Belimumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Belimumab may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib ... |
DB01229 | DB08865 | 973 | 1,593 | [
"DDInter1378",
"DDInter448"
] | Paclitaxel (protein-bound) | Crizotinib | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
973,
24,
1593
]
],
[
[
973,
5,
11582
],
[
11582,
44,
1593
]
],
[
[
973,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
973,
7,
10365
],
[
10365,... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Paclitaxel",
"{u} (Compound) treats {v} (Disease)",
"lung cancer"
],
[
"lung cancer",
"{u} (Disease) is treated ... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Paclitaxel (Compound) treats lung cancer (Disease) and lung cancer (Disease) is treated by Crizotinib (Compound)
Paclitaxel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Paclitaxel ... |
DB04861 | DB08907 | 1,592 | 1,344 | [
"DDInter1271",
"DDInter280"
] | Nebivolol | Canagliflozin | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1592,
24,
1344
]
],
[
[
1592,
24,
549
],
[
549,
1,
1344
]
],
[
[
1592,
21,
28681
],
[
28681,
60,
1344
]
],
[
[
1592,
63,
1486
],
[
148... | [
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Nebivolol (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Canagliflozin (Compound)
Nebivolol may cause ... |
DB00607 | DB11581 | 1,249 | 1,456 | [
"DDInter1256",
"DDInter1926"
] | Nafcillin | Venetoclax | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
1249,
25,
1456
]
],
[
[
1249,
24,
1135
],
[
1135,
23,
1456
]
],
[
[
1249,
25,
1476
],
[
1476,
63,
1456
]
],
[
[
1249,
24,
466
],
[
466... | [
[
[
"Nafcillin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Nafcillin may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a mode... |
DB01235 | DB04843 | 1,191 | 1,511 | [
"DDInter1054",
"DDInter1149"
] | Levodopa | Mepenzolate | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
1191,
24,
1511
]
],
[
[
1191,
63,
1192
],
[
1192,
24,
1511
]
],
[
[
1191,
21,
28975
],
[
28975,
60,
1511
]
],
[
[
1191,
24,
820
],
[
8... | [
[
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
[
... | Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Levodopa (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Mepenzolate (Comp... |
DB00526 | DB06663 | 1,555 | 1,154 | [
"DDInter1355",
"DDInter1398"
] | Oxaliplatin | Pasireotide | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
1555,
25,
1154
]
],
[
[
1555,
24,
112
],
[
112,
23,
1154
]
],
[
[
1555,
23,
1247
],
[
1247,
23,
1154
]
],
[
[
1555,
24,
663
],
[
663,
... | [
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metr... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole... |
DB00357 | DB08930 | 1,051 | 1,459 | [
"DDInter71",
"DDInter582"
] | Aminoglutethimide | Dolutegravir | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Minor | 0 | [
[
[
1051,
23,
1459
]
],
[
[
1051,
21,
28722
],
[
28722,
60,
1459
]
],
[
[
1051,
24,
1419
],
[
1419,
23,
1459
]
],
[
[
1051,
62,
1101
],
[
... | [
[
[
"Aminoglutethimide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolutegravir"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect)... | Aminoglutethimide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Dolutegravir (Compound)
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a minor interaction that can limit clinical effects when taken with Dol... |
DB00850 | DB11901 | 1,630 | 913 | [
"DDInter1432",
"DDInter107"
] | Perphenazine | Apalutamide | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1630,
24,
913
]
],
[
[
1630,
23,
112
],
[
112,
23,
913
]
],
[
[
1630,
63,
600
],
[
600,
24,
913
]
],
[
[
1630,
24,
28
],
[
28,
2... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Perphenazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Perphenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole an... |
DB00026 | DB06589 | 1,184 | 1,250 | [
"DDInter94",
"DDInter1400"
] | Anakinra | Pazopanib | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1184,
24,
1250
]
],
[
[
1184,
24,
651
],
[
651,
24,
1250
]
],
[
[
1184,
24,
1270
],
[
1270,
63,
1250
]
],
[
[
1184,
63,
305
],
[
305,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified pr... |
DB00682 | DB01036 | 126 | 211 | [
"DDInter1951",
"DDInter1832"
] | Warfarin | Tolterodine | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Moderate | 1 | [
[
[
126,
24,
211
]
],
[
[
126,
1,
358
],
[
358,
40,
211
]
],
[
[
126,
1,
11244
],
[
11244,
1,
211
]
],
[
[
126,
62,
1523
],
[
1523,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
]
],
[
[
"Warfarin",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} (Compound) resembl... | Warfarin (Compound) resembles Orphenadrine (Compound) and Orphenadrine (Compound) resembles Tolterodine (Compound)
Warfarin (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Tolterodine (Compound)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Labet... |
DB00427 | DB00902 | 1,233 | 104 | [
"DDInter1879",
"DDInter1168"
] | Triprolidine | Methdilazine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
1233,
24,
104
]
],
[
[
1233,
24,
13
],
[
13,
24,
104
]
],
[
[
1233,
24,
820
],
[
820,
1,
104
]
],
[
[
1233,
24,
537
],
[
537,
40... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Alimema... |
DB00405 | DB00902 | 128 | 104 | [
"DDInter517",
"DDInter1168"
] | Dexbrompheniramine | Methdilazine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
128,
24,
104
]
],
[
[
128,
24,
13
],
[
13,
24,
104
]
],
[
[
128,
24,
820
],
[
820,
1,
104
]
],
[
[
128,
24,
537
],
[
537,
40,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyprohept... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.